record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundobservational · manual state transition
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
evidence spans
Foundational composition patent for gantenerumab, a fully human IgG1 anti-Aβ antibody generated via MorphoSys HuCAL technology; binds dual N-terminal (AEFRHDSGY) and central (VHHQKLVFFAEDVG) Aβ epitopes on aggregated fibrillar forms.
WO2003070760A2 — Anti-amyloid beta antibodies and their use (assignee: F. Hoffmann-La Roche AG and MorphoSys AG) — Core IP for gantenerumab (trontinemab backbone), the anti-Aβ component now reformatted with Brain Shuttle TfR module as trontinemab; dual-epitope binding to aggregated Aβ fibrils is the distinguishing SAR claim. · curator_source · 10.1038/s41573-022-00608-4
conditions
Provenance
source title
WO2003070760A2 — Anti-amyloid beta antibodies and their use (assignee: F. Hoffmann-La Roche AG and MorphoSys AG) — Core IP for gantenerumab (trontinemab backbone), the anti-Aβ component now reformatted with Brain Shuttle TfR module as trontinemab; dual-epitope binding to aggregated Aβ fibrils is the distinguishing SAR claim.
doi
10.1038/s41573-022-00608-4
authors
reviewer:will-blair-bot
Foundational composition patent for gantenerumab, a fully human IgG1 anti-Aβ antibody generated via MorphoSys HuCAL technology; binds dual N-terminal (AEFRHDSGY) and central (VHHQKLVFFAEDVG) Aβ epitopes on aggregated fibrillar forms.
vs_8465a1e64c0370ef · source:WO2003070760A2 — Anti-amyloid beta antibodies and their use (assignee: F. Hoffmann-La Roche AG and MorphoSys AG) — Core IP for gantenerumab (trontinemab backbone), the anti-Aβ component now reformatted with Brain Shuttle TfR module as trontinemab; dual-epitope binding to aggregated Aβ fibrils is the distinguishing SAR claim.|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_40f375196c00dc63finding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_df9279525a08d147finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_5e921e957ea492cbfinding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_6b51d32fbaec928ffinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.